AGL Healthcare

agilon health, inc.

$87.79+1.34%

Price as of close on Nov 3, 2026 · Financials updated Oct 6, 2026

Basics

Sector: Healthcare
Industry: Medical Care Facilities
Country: United States
Market cap: 1.5B USD
Enterprise value: 1.4B USD
Full-time employees: 856

Overall health

Strength: growing faster than most peersgrowing faster than peers
Drawback: less profitable than most peersless profitable than peers
Drawback: its shares are priced higher than most peers relative to what it earnspriced higher than peers for its earnings
Drawback: higher risk than most peers: its share price swings more than most peers’ (beta 3.00 vs a peer median of 0.63) and less short-term liquidity (current ratio 1.08 vs a peer median of 2.59)higher risk: bigger price swings (beta 3.00 vs peers 0.63) and less liquidity (current ratio 1.08 vs peers 2.59)

Ranks #1,037 of 1,157 healthcare companies (bottom 11%)

See how it ranks against its peers

Worth knowing

Valuation signals disagree. Cheaper than 50% of peers on free cash flow, but only 0% on earnings.
Relative to its free cash flow, agilon health looks cheaper than 50% of peers; relative to its earnings, cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.
Loss over 12 months, profit last quarter. Lost money in the 12 months to June 2026, but made a $18M profit in the quarter to June 2026.
agilon health reported a net loss over the last twelve months, but its most recent quarter was profitable ($18M). One quarter isn't a trend, but it's closer to profitability than the 12-month figure suggests.
More volatile share price. Beta 3.00: tends to move more than the market.
agilon health's shares have swung more with the market than most peers' (beta 3.00, above the market's 1.0).

StockQuotient Score

26/ 100

Oct 5 26 → Nov 4 26

Valuation

Is the price right?

8/100

Weak

3/3 inputs reported · High confidence

Since last quarter: No major changeValuation also moves with the share price every day.

Why

Weaker than most peers on:

▼ Earnings yield
▼ EBITDA yield

Compare with peers

Behind the score

Sector-normalized EBITDA, earnings, and free cash flow yields.

Earnings yield-15.8%

SEC filings · 12 months to Jun 2026Negative (a loss or cash outflow), so it counts as zero whatever the share price30% base weight · Z-score -1.00Sector median: 0.0148 · MAD: 0.0148

EBITDA yield-20.1%

SEC filings · 12 months to Jun 2026Negative (a loss or cash outflow), so it counts as zero whatever the share price50% base weight · Z-score -1.00Sector median: 0.0401 · MAD: 0.0401

Free cash flow yield-5.8%

SEC filings · 12 months to Jun 2026 · operating cash flow − capital spendingNegative (a loss or cash outflow), so it counts as zero whatever the share price20% base weight · Z-score 0.00Sector median: 0.0000 · MAD: 0.0000

Other data (not scored)

Book yield15.4%

SEC filings · latest balance sheetReported valueInformational · 0% composite weightSector median: 0.3716 · MAD: 0.2313

Growth

Is it growing?

62/100

Moderate

3/3 inputs reported · High confidence

Since last quarter: No major change

Why

Stronger than most peers on:

▲ 3-yr revenue

Compare with peers

Behind the score

Revenue and earnings-per-share growth over one year, and revenue growth over three years.

Earnings per share growthUnavailable

Still loss-making, but the loss per share narrowed33% base weight · Z-score 0.29Sector median: 0.0976 · MAD: 0.2991

3-year revenue growth22.9%

SEC filings · 3 years to Jun 2026Reported value33% base weight · Z-score 2.03Sector median: 0.0584 · MAD: 0.0840

Revenue growth0.3%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score -0.59Sector median: 0.0609 · MAD: 0.0974

Profitability

Does it earn well?

16/100

Weak

3/3 inputs reported · High confidence

Since last quarter: ▲ Stronger

Operating margin rose 2.3 points to -5.2%

Why

Weaker than most peers on:

▼ ROIC
▼ ROA
▼ Operating margin

Compare with peers

Behind the score

Return on invested capital, operating margin, and return on assets.

Operating margin-5.2%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score -1.01Sector median: 0.0706 · MAD: 0.1217

Return on assets-14.6%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score -3.03Sector median: 0.0166 · MAD: 0.0537

Return on invested capital-162.2%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score -16.62Sector median: 0.0471 · MAD: 0.1004

Other data (not scored)

Gross margin0.2%

Yahoo Finance fallback · SEC figure unavailable or out of date · trailing 12 monthsReported valueInformational · 0% composite weightSector median: 0.4697 · MAD: 0.2310

Return on equity-102.1%

SEC filings · 12 months to Jun 2026Reported valueInformational · 0% composite weightSector median: 0.0330 · MAD: 0.1225

Risk

Debt, liquidity, price swings

Higher

Higher relative risk

3/3 inputs reported · High confidence

Since last quarter: No major change

Why

Weaker than most peers on:

▼ Beta
▼ Current ratio

Compare with peers

Behind the score

Relative to sector peers: 0 = lower relative risk · 1 = moderate · 2 = higher. Based on leverage, beta and liquidity.

Beta3.00

Yahoo Finance · 5-year monthly beta vs the marketOutlier capped at sector 5th/95th percentile33% base weight · Z-score -4.28Sector median: 0.6250 · MAD: 0.3380

Current ratio1.08×

SEC filings · latest balance sheetReported value33% base weight · Z-score -1.09Sector median: 2.5860 · MAD: 1.3850

Debt / equity0.13×

SEC filings · latest balance sheetReported value33% base weight · Z-score 0.43Sector median: 0.2215 · MAD: 0.2039

Valuation, growth and profitability scores: higher is better. Risk: 0 is lower, 2 is higher. Risk is a relative proxy, not a bankruptcy probability. Scores depend on available sector peers.

Questions investors ask about agilon health

Is agilon health getting weaker?: Its latest SEC filing (Aug 5, 2026) got stronger: operating margin rose 2.3 points to -5.2%. Its overall score is unchanged at 26/100 since Oct 28, 2026.
How is agilon health valued vs its peers?: Priced higher than most peers relative to what it earns. Valuation scores 8/100 against 1,393 healthcare peers. Earnings yield -15.8% vs a peer median of 1.5% (weaker than 100% of peers).Earnings yield -15.8% vs peers 1.5% (weaker than 100% of peers).
Is agilon health growing?: Yes, faster than most of its peers. Growth scores 62/100 against 1,393 healthcare peers. 3-year revenue growth 22.9% vs a peer median of 5.8% (stronger than 83% of peers).3-year revenue growth 22.9% vs peers 5.8% (stronger than 83% of peers). Revenue growth 0.3% vs a peer median of 6.1% (weaker than 68% of peers).Revenue growth 0.3% vs peers 6.1% (weaker than 68% of peers).
How profitable is agilon health?: Less profitable than most of its peers. Profitability scores 16/100 against 1,393 healthcare peers. Return on invested capital -162.2% vs a peer median of 4.7% (weaker than 95% of peers).Return on invested capital -162.2% vs peers 4.7% (weaker than 95% of peers).
How risky is agilon health?: Higher risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Debt / equity 0.13× vs a peer median of 0.22× (stronger than 64% of peers).Debt / equity 0.13× vs peers 0.22× (stronger than 64% of peers). Beta 3.00 vs a peer median of 0.63 (weaker than 100% of peers).Beta 3.00 vs peers 0.63 (weaker than 100% of peers). A relative measure, not a bankruptcy probability.

Latest filing: what changed

Quarter ended Jun 30, 2026 · filed Aug 5, 2026 · compared with the quarter ended Mar 31, 2026

Got stronger

Operating margin rose 2.3 points to -5.2%

Worth watching: agilon health is in the bottom fifth of its sector on profitability. From 2021 to 2025, 63% of companies in that position posted a loss over the following year, against 4% for the top fifth.

	Previous quarter	Latest quarter	Change
Revenue (12 months)	5.8B USD	5.9B USD	+1.7%
Net income (12 months)	−354.5M USD	−232.2M USD	−34.5%
Operating margin	-7.5%	-5.2%	+2.3 pts
Free cash flow (12 months)	−62.5M USD	−85.0M USD	+35.8%
Debt	30.0M USD	30.3M USD	+0.9%
Cash	140.0M USD	107.2M USD	−23.4%
Shares outstanding	16.7M	16.8M	+0.6%

From the company’s own SEC filings, as filed. Twelve-month figures roll forward one quarter at a time.

Industry valuation context

Industry: Medical Care Facilities · 27 companies

Valuations in Medical Care Facilities are within their usual range since Jun 2017.

39% of months since Jun 2017 were valued lower than now.
28% of companies are in the most expensive fifth of their own price-to-sales history.
Median price-to-sales is −61% vs the whole market, against a usual −56%.

Jun 2017Shaded: most expensive fifth of its range2026

Financials

Fiscal years from SEC annual filings · change vs the prior year

Key ratios	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	Change
Operating margin	-24.5%	-4.4%	-5.4%	-4.8%	-7.8%	▼ 3.0 pts
Net margin	-26.7%	-4.5%	-6.1%	-4.3%	-6.6%	▼ 2.3 pts
Return on assets (ROA)	-25.6%	-6.3%	-15.1%	-15.0%	-30.8%	▼ 16 pts
Return on equity (ROE)	-37.2%	-10.2%	-39.7%	-55.2%	-308.8%	▼ 254 pts
Free cash flow margin	-10.2%	-6.1%	-4.0%	-1.2%	-2.0%	▼ 0.8 pts
Current ratio	3.83×	2.71×	1.51×	1.27×	1.02×	▼ 19%
Debt to equity	0.04×	0.04×	0.06×	0.07×	0.28×	▲ 273%
Interest coverage	-60.57×	-23.50×	-34.87×	-47.29×	-69.75×	▼ 47%

AGL price history

Price history is added with the daily price update and will appear after the next one.

Similar companies

Sector leaderboards

BB Biotech AGBBZA.DE100/ 100

Arbutus Biopharma CorporationABUS97/ 100

Q32 Bio Inc.QTTB97/ 100

Bringing the fundamentals into focus…

Overall health

Strength: growing faster than most peersgrowing faster than peers

Drawback: less profitable than most peersless profitable than peers

Drawback: its shares are priced higher than most peers relative to what it earnspriced higher than peers for its earnings

Drawback: higher risk than most peers: its share price swings more than most peers’ (beta 3.00 vs a peer median of 0.63) and less short-term liquidity (current ratio 1.08 vs a peer median of 2.59)higher risk: bigger price swings (beta 3.00 vs peers 0.63) and less liquidity (current ratio 1.08 vs peers 2.59)

Ranks #1,037 of 1,157 healthcare companies (bottom 11%)

See how it ranks against its peers

Worth knowing

Valuation signals disagree. Cheaper than 50% of peers on free cash flow, but only 0% on earnings.

Relative to its free cash flow, agilon health looks cheaper than 50% of peers; relative to its earnings, cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.

Loss over 12 months, profit last quarter. Lost money in the 12 months to June 2026, but made a $18M profit in the quarter to June 2026.

agilon health reported a net loss over the last twelve months, but its most recent quarter was profitable ($18M). One quarter isn't a trend, but it's closer to profitability than the 12-month figure suggests.

More volatile share price. Beta 3.00: tends to move more than the market.

agilon health's shares have swung more with the market than most peers' (beta 3.00, above the market's 1.0).

Questions investors ask about agilon health

Is agilon health getting weaker?

Its latest SEC filing (Aug 5, 2026) got stronger: operating margin rose 2.3 points to -5.2%. Its overall score is unchanged at 26/100 since Oct 28, 2026.

How is agilon health valued vs its peers?

Priced higher than most peers relative to what it earns. Valuation scores 8/100 against 1,393 healthcare peers. Earnings yield -15.8% vs a peer median of 1.5% (weaker than 100% of peers).Earnings yield -15.8% vs peers 1.5% (weaker than 100% of peers).

Is agilon health growing?

Yes, faster than most of its peers. Growth scores 62/100 against 1,393 healthcare peers. 3-year revenue growth 22.9% vs a peer median of 5.8% (stronger than 83% of peers).3-year revenue growth 22.9% vs peers 5.8% (stronger than 83% of peers). Revenue growth 0.3% vs a peer median of 6.1% (weaker than 68% of peers).Revenue growth 0.3% vs peers 6.1% (weaker than 68% of peers).

How profitable is agilon health?

Less profitable than most of its peers. Profitability scores 16/100 against 1,393 healthcare peers. Return on invested capital -162.2% vs a peer median of 4.7% (weaker than 95% of peers).Return on invested capital -162.2% vs peers 4.7% (weaker than 95% of peers).

How risky is agilon health?

Higher risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Debt / equity 0.13× vs a peer median of 0.22× (stronger than 64% of peers).Debt / equity 0.13× vs peers 0.22× (stronger than 64% of peers). Beta 3.00 vs a peer median of 0.63 (weaker than 100% of peers).Beta 3.00 vs peers 0.63 (weaker than 100% of peers). A relative measure, not a bankruptcy probability.

Previous quarter

Latest quarter

Change

Revenue (12 months)

5.8B USD

5.9B USD

+1.7%

Net income (12 months)

−354.5M USD

−232.2M USD

−34.5%

Operating margin

-7.5%

-5.2%

+2.3 pts

Free cash flow (12 months)

−62.5M USD

−85.0M USD

+35.8%

Debt

30.0M USD

30.3M USD

+0.9%

Cash

140.0M USD

107.2M USD

−23.4%

Shares outstanding

16.7M

16.8M

+0.6%

Key ratios

FY 2021

FY 2022

FY 2023

FY 2024

FY 2025

Change

Operating margin

-24.5%

-4.4%

-5.4%

-4.8%

-7.8%

▼ 3.0 pts

Net margin

-26.7%

-4.5%

-6.1%

-4.3%

-6.6%

▼ 2.3 pts

Return on assets (ROA)

-25.6%

-6.3%

-15.1%

-15.0%

-30.8%

▼ 16 pts

Return on equity (ROE)

-37.2%

-10.2%

-39.7%

-55.2%

-308.8%

▼ 254 pts

Free cash flow margin

-10.2%

-6.1%

-4.0%

-1.2%

-2.0%

▼ 0.8 pts

Current ratio

3.83×

2.71×

1.51×

1.27×

1.02×

▼ 19%

Debt to equity

0.04×

0.06×

0.07×

0.28×

▲ 273%

Interest coverage

-60.57×

-23.50×

-34.87×

-47.29×

-69.75×

▼ 47%